IFNG and leukemia: However, only dasatinib was effective at clinically relevant concentrations; 50 nM inhibited TNF-α and IFN-γ secretion, with only a slight reduction in cytotoxicity toward leukemia cells and allowed effective control of CAR-T cell cytotoxicity against endothelial cells in relation to the inhibition of cytokine secretion.